- AimedBio's 'AMB001' has been selected as a "study on the establishment of novel therapeutics R&D ecosystem" project by the Korean Drug Development Project (KDDF). It will receive research funds to derive its candidate over the next two years.
- AMB001 is an immune antibody that targets upper receptors that suppress inflammatory reactions and treats allergic diseases caused by excessive inflammatory reactions.
- AMB001 is being developed with atopic dermatitis and chronic sinusitis as its main indicators, but AimedBio is also considering various allergic diseases and autoimmune diseases as areas of indication expansion.